Browsing Tag
rare disease therapeutics
2 posts
Is setmelanotide the first true disease-targeted therapy for hypothalamic obesity?
Is setmelanotide redefining hypothalamic obesity treatment? Explore what Rhythm Pharmaceuticals, Inc.’s EU approval means for markets and growth.
Why YolTech Therapeutics believes YOLT-202 could become a “one-and-done” treatment for Alpha-1 Antitrypsin Deficiency
YolTech Therapeutics receives FDA clearance to launch a Phase 2/3 trial of YOLT-202 for Alpha-1 Antitrypsin Deficiency. Discover what this means for gene editing.